|
Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma. |
|
|
Consulting or Advisory Role - Achilles Therapeutics; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Rakuten Medical; Sanofi |
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Roche |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gliknik; Janssen Oncology; Kura Oncology; Merck Sharp & Dohme; Nanobiotix; Novartis; Orion; Pfizer; Roche; Seagen (Inst); Shattuck Labs |
Travel, Accommodations, Expenses - AstraZeneca Spain; Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - GlaxoSmithKline |
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca; Athenex; Clovis Oncology; FORMA Therapeutics; Immutep; Iovance Biotherapeutics; Nucana; PsiOxus Therapeutics; Replimune; Sierra Oncology; Starpharma; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Novartis; Pfizer; Roche |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche |
|
|
|
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Janssen; OM Pharma; Roche; Seagen |
|
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; Immutep |
|
|
|
Stock and Other Ownership Interests - Abbvie; Bayer Holding; Immutep |
Consulting or Advisory Role - Astellas Pharma |
|
|
|
Stock and Other Ownership Interests - Immutep |
Patents, Royalties, Other Intellectual Property - Being an inventor on patents on LAG-3 owned by Immutep SAS |